Intra-lesional interleukin-2 therapy for in transit melanoma
- PMID: 24453036
- DOI: 10.1002/jso.23556
Intra-lesional interleukin-2 therapy for in transit melanoma
Abstract
Intra-lesional interleukin-2 (IL-2) is effective in treating in transit melanoma metastases. Results from multiple studies were examined to evaluate the efficacy of IL-2 for in transit disease. In the published literature, complete response ranged from 0% to 69% per patient, and 41% to 96% per lesion, with excellent tolerability. Combining the results of six studies show complete response in 50% of patients and 78% of lesions. Intra-lesional IL-2 should be considered early in the course of treatment for in transit disease, ahead of other, more toxic therapies.
Keywords: in-transit melanoma; interleukin-2; intra-lesional; melanoma.
© 2014 Wiley Periodicals, Inc.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
